Is Virax Biolabs Stock a Good Investment?
Virax Biolabs Investment Advice | VRAX |
- Examine Virax Biolabs' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Virax Biolabs' leadership team and their track record. Good management can help Virax Biolabs navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Virax Biolabs' business and its evolving consumer preferences.
- Compare Virax Biolabs' performance and market position to its competitors. Analyze how Virax Biolabs is positioned in terms of product offerings, innovation, and market share.
- Check if Virax Biolabs pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Virax Biolabs' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Virax Biolabs Group stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Virax Biolabs Group is a good investment.
Sell | Buy |
Hold
Market Performance | Very Weak | Details | |
Volatility | Risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Sell | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Virax Biolabs Stock
Researching Virax Biolabs' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company has Price to Book (P/B) ratio of 1.04. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Virax Biolabs Group recorded a loss per share of 2.61. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 18th of December 2023.
To determine if Virax Biolabs is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Virax Biolabs' research are outlined below:
| Virax Biolabs Group generated a negative expected return over the last 90 days | |
| Virax Biolabs Group has high historical volatility and very poor performance | |
| Virax Biolabs Group may become a speculative penny stock | |
| Virax Biolabs Group currently holds 224.3 K in liabilities. Virax Biolabs Group has a current ratio of 0.04, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Virax Biolabs' use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 156.42 K. Net Loss for the year was (6.74 M) with loss before overhead, payroll, taxes, and interest of (1.36 K). | |
| Virax Biolabs Group currently holds about 21.76 K in cash with (6.25 M) of positive cash flow from operations. | |
| Latest headline from simplywall.st: Virax Biolabs Group First Half 2025 Earnings US0.89 loss per share |
Virax Biolabs Quarterly Liabilities And Stockholders Equity |
|
Virax Biolabs uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Virax Biolabs Group. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Virax Biolabs' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of September 2023 Upcoming Quarterly Report | View | |
| 30th of June 2023 Next Fiscal Quarter End | View | |
| 12th of June 2024 Next Fiscal Year End | View | |
| 31st of March 2023 Last Quarter Report | View | |
| 31st of March 2023 Last Financial Announcement | View |
Know Virax Biolabs' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Virax Biolabs is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Virax Biolabs Group backward and forwards among themselves. Virax Biolabs' institutional investor refers to the entity that pools money to purchase Virax Biolabs' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Renaissance Technologies Corp | 2024-09-30 | 145.4 K | Virtu Financial Llc | 2024-06-30 | 28.1 K | Hrt Financial Llc | 2024-06-30 | 25.7 K | Ubs Group Ag | 2024-06-30 | 5.6 K | Qube Research & Technologies | 2024-06-30 | 300 | Headlands Technologies Llc | 2024-09-30 | 185 | Wells Fargo & Co | 2024-06-30 | 100.0 | Citadel Advisors Llc | 2024-06-30 | 0.0 |
Virax Biolabs' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 8.99 M.Market Cap |
|
Virax Biolabs' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.24) | (1.30) | |
| Return On Capital Employed | (1.22) | (1.16) | |
| Return On Assets | (1.23) | (1.29) | |
| Return On Equity | (1.25) | (1.19) |
Determining Virax Biolabs' profitability involves analyzing its financial statements and using various financial metrics to determine if Virax Biolabs is a good buy. For example, gross profit margin measures Virax Biolabs' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Virax Biolabs' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Virax Biolabs' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Virax Biolabs Group. Check Virax Biolabs' Beneish M Score to see the likelihood of Virax Biolabs' management manipulating its earnings.
Evaluate Virax Biolabs' management efficiency
Virax Biolabs Group has return on total asset (ROA) of (0.499) % which means that it has lost $0.499 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9598) %, meaning that it created substantial loss on money invested by shareholders. Virax Biolabs' management efficiency ratios could be used to measure how well Virax Biolabs manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.3 in 2024. Return On Capital Employed is likely to rise to -1.16 in 2024. At this time, Virax Biolabs' Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 1.2 M in 2024, whereas Total Assets are likely to drop slightly above 3.4 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.56 | 1.30 | |
| Tangible Book Value Per Share | 2.54 | 1.27 | |
| Enterprise Value Over EBITDA | 0.29 | 0.30 | |
| Price Book Value Ratio | 0.27 | 0.29 | |
| Enterprise Value Multiple | 0.29 | 0.30 | |
| Price Fair Value | 0.27 | 0.29 | |
| Enterprise Value | -1.9 M | -2 M |
Evaluating the management effectiveness of Virax Biolabs allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Virax Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Beta 1.925 |
Basic technical analysis of Virax Stock
As of the 29th of November, Virax Biolabs has the Variance of 83.12, coefficient of variation of (981.29), and Risk Adjusted Performance of (0.07). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Virax Biolabs Group, as well as the relationship between them.Understand Virax Biolabs' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Virax Biolabs' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | 2.2 | |||
| Mean Deviation | 5.67 | |||
| Coefficient Of Variation | (981.29) | |||
| Standard Deviation | 9.12 | |||
| Variance | 83.12 | |||
| Information Ratio | (0.12) | |||
| Jensen Alpha | (0.89) | |||
| Total Risk Alpha | (2.31) | |||
| Treynor Ratio | 2.19 | |||
| Maximum Drawdown | 61.28 | |||
| Value At Risk | (12.90) | |||
| Potential Upside | 9.65 | |||
| Skewness | 2.76 | |||
| Kurtosis | 14.41 |
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | 2.2 | |||
| Mean Deviation | 5.67 | |||
| Coefficient Of Variation | (981.29) | |||
| Standard Deviation | 9.12 | |||
| Variance | 83.12 | |||
| Information Ratio | (0.12) | |||
| Jensen Alpha | (0.89) | |||
| Total Risk Alpha | (2.31) | |||
| Treynor Ratio | 2.19 | |||
| Maximum Drawdown | 61.28 | |||
| Value At Risk | (12.90) | |||
| Potential Upside | 9.65 | |||
| Skewness | 2.76 | |||
| Kurtosis | 14.41 |
Consider Virax Biolabs' intraday indicators
Virax Biolabs intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Virax Biolabs stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 1010.2 | |||
| Daily Balance Of Power | (1.67) | |||
| Rate Of Daily Change | 0.95 | |||
| Day Median Price | 1.99 | |||
| Day Typical Price | 1.98 | |||
| Price Action Indicator | (0.07) | |||
| Period Momentum Indicator | (0.10) |
Virax Biolabs Corporate Filings
6K | 20th of November 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
| 30th of September 2024 Other Reports | ViewVerify | |
| 20th of August 2024 Other Reports | ViewVerify |
Virax Stock media impact
Far too much social signal, news, headlines, and media speculation about Virax Biolabs that are available to investors today. That information is available publicly through Virax media outlets and privately through word of mouth or via Virax internal channels. However, regardless of the origin, that massive amount of Virax data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Virax Biolabs news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Virax Biolabs relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Virax Biolabs' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Virax Biolabs alpha.
Virax Biolabs Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Virax Biolabs can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Virax Biolabs Corporate Management
| Tomasz George | Chief Officer | Profile | |
| Joel Yeung | Accounting Manager | Profile | |
| Nigel MSc | Chief Officer | Profile | |
| Cameron Shaw | COO Director | Profile | |
| James Wang | Head Sourcing | Profile | |
| James Foster | Chairman CEO | Profile |
Additional Tools for Virax Stock Analysis
When running Virax Biolabs' price analysis, check to measure Virax Biolabs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virax Biolabs is operating at the current time. Most of Virax Biolabs' value examination focuses on studying past and present price action to predict the probability of Virax Biolabs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virax Biolabs' price. Additionally, you may evaluate how the addition of Virax Biolabs to your portfolios can decrease your overall portfolio volatility.